Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy.
Better markers for determining therapeutic efficacy of antiretroviral drugs are needed for human immunodeficiency virus (HIV) infection. The amounts of unintegrated HIV DNA (uDNA) were sequentially determined in peripheral blood mononuclear cells (PBMC) from 20 HIV-infected patients starting nucleoside therapy. HIV copy number was determined using a quantitative polymerase chain reaction assay. Before therapy, 19 of 20 patients had detectable HIV uDNA. The average percentage of uDNA was 42%. After 1, 4, and 8 weeks of nucleoside therapy the average decreased to 23% (P < .001), 7%, and 3%, respectively. The amount of HIV uDNA decreased in all 19 patients during the first week and was undetectable in 14 by 8 weeks. Thus, measurement of HIV uDNA has many characteristics needed for a good marker of therapeutic efficacy of antiretroviral drugs, including detectability in a high proportion of patients, large and rapid response to initiation of therapy, and a biologically plausible mechanism.
Donovan
R M
RM
Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202.
Bush
C E
CE
Smereck
S M
SM
Baxa
D M
DM
Markowitz
N P
NP
Saravolatz
L D
LD
D000328:Adult; D004279:DNA, Viral / Q000378:metabolism*; D005819:Genetic Markers; D015658:HIV Infections / Q000188:drug therapy* / Q000382:microbiology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D016662:Virus Integration
D004279:DNA, Viral; D005819:Genetic Markers; D009705:Nucleosides